Stockscreener 앱 받기
5.00
0.60%
0.03
전일 마감가:
$4.97
열려 있는:
$4.97
하루 거래량:
626.73K
Relative Volume:
0.43
시가총액:
$501.50M
수익:
$775.09M
순이익/손실:
$-58.68M
주가수익비율:
-37.71
EPS:
-0.1326
순현금흐름:
$64.06M
1주 성능:
+6.84%
1개월 성능:
+1.83%
6개월 성능:
+1.01%
1년 성능:
-42.79%
1일 변동 폭
$4.94
$5.01
1주일 범위
$4.71
$5.06
52주 변동 폭
$3.675
$9.165
Goodrx Holdings Inc Stock (GDRX) Company Profile
명칭
Goodrx Holdings Inc
전화
(855) 268-2822
주소
2701 OLYMPIC BOULEVARD, SANTA MONICA
GDRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
5.00 | 1.78B | 775.09M | -58.68M | 64.06M | -0.1326 |
|
VEEV
Veeva Systems Inc
|
290.41 | 47.59B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
64.49 | 10.97B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
60.77 | 11.37B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
96.04 | 8.16B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.83 | 6.40B | 906.14M | -52.62M | 89.62M | -0.3621 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-04 | 개시 | Mizuho | Neutral |
| 2024-08-09 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-02-26 | 개시 | Leerink Partners | Outperform |
| 2024-01-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-08-10 | 업그레이드 | DA Davidson | Neutral → Buy |
| 2023-07-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | 개시 | Citigroup | Buy |
| 2022-11-04 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-08-12 | 개시 | DA Davidson | Neutral |
| 2022-06-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-06-06 | 재개 | BofA Securities | Buy |
| 2022-06-01 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-05-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | 개시 | Wells Fargo | Equal Weight |
| 2022-04-07 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Neutral |
| 2022-03-15 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | 재확인 | Barclays | Overweight |
| 2022-03-01 | 재확인 | BofA Securities | Neutral |
| 2022-03-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-01 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | 재확인 | Evercore ISI | Outperform |
| 2022-03-01 | 재확인 | Goldman | Buy |
| 2022-03-01 | 재확인 | JP Morgan | Underweight |
| 2022-03-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-03-01 | 재확인 | SVB Leerink | Outperform |
| 2022-01-07 | 개시 | Goldman | Buy |
| 2021-12-21 | 개시 | Stephens | Overweight |
| 2021-12-02 | 개시 | Jefferies | Buy |
| 2021-08-31 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-08-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | 개시 | Robert W. Baird | Neutral |
| 2021-04-06 | 재개 | Evercore ISI | Outperform |
| 2021-01-25 | 개시 | Guggenheim | Buy |
| 2020-11-19 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | 개시 | Barclays | Equal Weight |
| 2020-10-19 | 개시 | BofA Securities | Neutral |
| 2020-10-19 | 개시 | Citigroup | Buy |
| 2020-10-19 | 개시 | Cowen | Outperform |
| 2020-10-19 | 개시 | Credit Suisse | Outperform |
| 2020-10-19 | 개시 | Deutsche Bank | Hold |
| 2020-10-19 | 개시 | Goldman | Neutral |
| 2020-10-19 | 개시 | JP Morgan | Neutral |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
| 2020-10-19 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | 개시 | SVB Leerink | Outperform |
| 2020-10-19 | 개시 | UBS | Buy |
모두보기
Goodrx Holdings Inc 주식(GDRX)의 최신 뉴스
Is GoodRx Holdings Inc. a good long term investmentOver 200% growth - PrintWeekIndia
What drives GoodRx Holdings Inc. stock priceExceptional earning trajectories - PrintWeekIndia
Exploring High Growth Tech Stocks in the US This July 2025 - simplywall.st
What institutions are buying GoodRx Holdings Inc. stock nowUnmatched profit potential - jammulinksnews.com
GoodRx Holdings Inc. Stock Analysis and ForecastUnmatched market performance - jammulinksnews.com
Jim Cramer Holds Back on GoodRx (GDRX) - MSN
Google, Meta Can't Escape GoodRx Health Data Sharing Suit - Law360
What analysts say about GoodRx Holdings Inc. stockSky-high return potential - jammulinksnews.com
GOODRX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of GoodRx Holdings, Inc.GDRX - The Globe and Mail
Is GoodRx Holdings Inc. stock a good hedge against inflationChart Based Entries - Newser
Why GoodRx Holdings Inc. stock attracts strong analyst attentionSolid Return Trade Selections - beatles.ru
OPRX Vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum? - Barchart.com
OPRX vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum? - TradingView
What makes GoodRx Holdings Inc. stock price move sharplyBig Profit Small Risk Alerts - Newser
Riot Platforms selling more Bitfarms (BITF) - The Globe and Mail
Leerink Partners Remains Bullish on GoodRx Holdings (GDRX) - Yahoo Finance
Undervalued Opportunities: Penny Stocks Worth Watching In July 2025 - simplywall.st
GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Rating of “Moderate Buy” by Analysts - Defense World
GoodRx Holdings Announces Q2 2025 Financial Results Release Date - AInvest
GoodRx Announces Date for Second Quarter 2025 Earnings Release and Conference Call - Business Wire
GDRX vs. HQY: Which Stock Is the Better Value Option? - Yahoo Finance
GoodRx: A One Big Beautiful Bill Act Beneficiary - Seeking Alpha
Goodrx Holdings Inc (GDRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.21%
1.00%
자본화:
|
볼륨(24시간):